Interphase cytogenetic analysis of serous ovarian tumors of low malignant potential: Comparison with serous cystadenomas and invasive serous carcinomas

Laboratory Investigation

Volumn 75, Issue 4, 1996, Pages 473-485

  Diebold, Joachim ^a   Deisenhofer, Isabel ^a   Baretton, Gustavo Bruno ^a   Blasenbreu, Sabine ^a   Suchy, Bernhard ^a   Schneiderbanger, Karin ^a   Meier, Werner ^a   Haas, Christian Josef ^a   Löhrs, Udo ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARCINOGENESIS; CHROMOSOME 1; CHROMOSOME 6; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYSTADENOMA; CYTOGENETICS; DNA DETERMINATION; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOLECULAR GENETICS; OVARY CARCINOMA; OVARY TUMOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; X CHROMOSOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CHROMOSOME ABERRATIONS; CYSTADENOMA, SEROUS; DNA; FEMALE; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION; INTERPHASE; MIDDLE AGED; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PHENOTYPE; PLOIDIES; POLYMERASE CHAIN REACTION;

EID: 0029999506     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Baretton G, Diebold J, DePascale T, Bussar-Maatz R, Weissbach L, and Löhrs U (1994a). Deoxyribonucleic acid ploidy in seminomas with and without syncytiotrophoblastic cells. J Urol 151:67-71.
2. Baretton G, Müller M, Schneiderbanger K, Wirtz A, Wisser J, Arnholdt H, and Löhrs U (1995). Cytogenetic aberrations in abortions: Correlation of conventional karyotyping and interphase cytogenetics on tissue sections and nuclear suspensions (abstract). Pathol Res Pract 191:206.
3. Baretton GB, Valina C, Vogt T, Schneiderbanger K, Diebold J, and Löhrs U (1994b). Interphase cytogenetic analysis of prostatic carcinomas by use of nonisotopic in situ hybridization. Cancer Res 54:4472-4480.
4. Bell DA (1991). Ovarian surface epithelial-stromal tumors. Hum Pathol 22:750-762.
5. Bello MJ and Rey JA (1990). Chromosome aberrations in metastatic ovarian cancer: Relationship with abnormalities in primary tumors. Int J Cancer 45:50-54.
6. Berchuck A, Kohler MF, Hopkins MP, Humphrey PA, Robboy SJ, Rodriguez GC, Soper JT, Clarke Pearson DL, and Bast RC (1994). Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecol Oncol 52:232-236.
7. Berchuck A, Rodriguez GC, Kamel A, Dodge RK, Soper JT, Clarke Pearson DL, and Bast RCJ (1991). Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol 164:669-674.
8. Braly PS and Klevecz RR (1993). Flow cytometric evaluation of ovarian cancer. Cancer 71:1621-1628.
9. Brodeur GM (1994). The NF1 gene in myelopoiesis and childhood myelodysplastic syndromes. N Engl J Med 330: 637-639.
10. Cordon-Cardo C (1995). Mutation of cell cycle regulators: Biological and clinical implications for human neoplasia. Am J Pathol 147:545-560.
11. Diebold J, Baretton G, Felchner M, Meier W, Dopfer K, Schmidt M, and Löhrs U (1996a). Bcl2 expression, p53 accumulation and apoptosis in ovarian carcinomas. Am J Clin Pathol 105:341-349.
12. Diebold J, Suchy B, Baretton GB, Blasenbreu S, Meier W, Schmidt M, Rabes H and Löhrs U (in press, 1996). DNA ploidy and myc DNA amplification in ovarian carcinomas: Correlation with p53 and bcl-2 expression, proliferative acticity and prognosis. Virchows Arch.
13. Dodson MK, Hartmann LC, Cliby WA, DeLacey KA, Keeney GL, Ritland SR, Su JQ, Podratz KC, and Jenkins RB (1993). Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas. Cancer Res 53:4456-4460.
14. Ehlen T and Dubeau L (1990). Loss of heterozygosity on chromosomal segments 3p, 6q and 11p in human ovarian carcinomas. Oncogene 5:219-223.
15. Elchalal U, Dgani R, Piura B, Anteby SO, Zalel Y, Czernobilsky B, and Schenker JG (1995). Current concepts in management of epithelial ovarian tumors of low malignant potential. Obstet Gynecol Surv 50:62-70.
16. Elfving P, Cigudosa JC, Lundgren R, Limon J, Mandahl N, Kristoffersson U, Heim S, and Mitelman F (1990). Trisomy 7, trisomy 10, and loss of the Y chromosome in short-term cultures of normal kidney tissue. Cytogenet Cell Genet 53: 123-125.
17. El Naggar AK, van Dekken HD, Ensign LG, and Pathak S (1994). Interphase cytogenetics in paraffin-embedded sections from renal cortical neoplasms. Correlation with cytogenetic and flow cytometric DNA ploidy analyses. Cancer Genet Cytogenet 73:134-141.
18. Foulkes WD, Ragoussis J, Stamp GW, Allan GJ, and Trowsdale J (1993). Frequent loss of heterozygosity on chromosome 6 in human ovarian carcinoma. Br J Cancer 67:551-559.
19. Grzeschik KH, Tsui LC, and Green ED (1994). Report and abstracts of the First International Workshop on Human Chromosome 7 Mapping 1993. Cytogenet Cell Genet 65:52-73.
20. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, and Musgrove EA (1983). Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 31:1333-1335.
21. Heim S, Mandahl N, Jin Y, Stromblad S, Lindstrom E, Salford LG, and Mitelman F (1989). Trisomy 7 and sex chromosome loss in human brain tissue. Cytogenet Cell Genet 52:136-138.
22. Heim S and Mitelman F (1995). Cancer cytogenetics. New York: Wiley-Liss.
23. Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M, and Oberg K (1993). Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 53:4550-4554.
24. Hopman AH, Poddighe PJ, Smeets AW, Moesker O, Beck JL, Vooijs GP, and Ramaekers FC (1989a). Detection of numerical chromosome aberrations in bladder cancer by in situ hybridization. Am J Pathol 135:1105-1117.
25. Hopman AH, Ramaekers FCS, and Vooijs GP (1989b). Interphase cytogenetics of solid tumors. In: Polak JM and McGee JO, editors. In situ hybridization: Principles and practice. Oxford: Oxford University Press, 165.
26. Hopman AH, van Hooren E, van de Kaa CA, Vooijs PG, and Ramaekers FC (1991). Detection of numerical chromosome aberrations using in situ hybridization in paraffin sections of routinely processed bladder cancers. Mod Pathol 4:503-513.
27. Iwabuchi H, Sakamoto M, Sakunaga H, Ma YY, Carcangiu ML, Pinkel D, Yang Feng TL, and Gray JW (1995). Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer Res 55:6172-6180.
28. Jenkins RB, Bartelt D, Stalboerger P, Persons D, Dahl RJ, Podratz K, Keeney G, and Hartmann L (1993). Cytogenetic studies of epithelial ovarian carcinoma. Cancer Genet Cytogenet 71:76-86.
29. Jones MH and Nakamura Y (1992). Deletion mapping of chromosome 3p in female genital tract malignancies using microsatellite polymorphisms. Oncogene 7:1631-1634.
30. Kaern J, Trope CG, and Abeler VM (1993). A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982: A review of clinicopathologic features and treatment modalities. Cancer 71:1810-1820.
31. Kim SY, Lee JS, Ro JY, Gay ML, Hong WK, and Hittelman WN (1993). Interphase cytogenetics in paraffin sections of lung tumors by non-isotopic in situ hybridization: Mapping genotype/phenotype heterogeneity. Am J Pathol 142:307-317.
32. Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke Pearson DL, Soper JT, Bast RC, and Berchuck A (1993). Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 85:1513-1519.
33. Kupryjanczyk J, Thor AD, Beauchamp R, Merritt V, Edgerton SM, Bell DA, and Yandell DW (1993). p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 90:4961-4965.
34. Lastowska MA, Lillington DM, Shelling AN, Cooke I, Gibbons B, Young BD, and Ganesan TS (1994). Fluorescence in situ hybridization analysis using cosmid probes to define chromosome 6q abnormalities in ovarian carcinoma cell lines. Cancer Genet Cytogenet 77:99-105.
35. Lee JH, Kavanagh JJ, Wildrick DM, Wharton JT, and Blick M (1990). Frequent loss of heterozygosity on chromosomes 6q, 11, and 17 in human ovarian carcinomas. Cancer Res 50: 2724-2728.
36. Liehr T, Stubinger A, Thoma K, Tulusan HA, and Gebhart E (1994). Comparative interphase cytogenetics using FISH on human ovarian carcinomas. Anticancer Res 14:183-188.
37. Ljungberg B, Forsslund G, Stenling R, and Zetterberg A (1986). Prognostic significance of the DNA content in renal cell carcinoma. J Urol 135:422-426.
38. Osborne RJ and Leech V (1994). Polymerase chain reaction allelotyping of human ovarian cancer. Br J Cancer 69:429-438.
39. Pandis N, Bardi G, and Heim S (1994). Interrelationship between methodological choices and conceptual models in solid tumor cytogenetics. Cancer Genet Cytogenet 76:77-84.
40. Pejovic T, Heim S, Mandahl N, Baldetorp B, Elmfors B, Floderus UM, Furgyik S, Helm G, Himmelmann A, Willen H, and Mitelman F (1992a). Chromosome aberrations in 35 primary ovarian carcinomas. Genes Chromosom Cancer 4:58-68.
41. Pejovic T, Heim S, Orndal C, Jin YS, Mandahl N, Willen H, and Mitelman F (1990). Simple numerical chromosome aberrations in well-differentiated malignant epithelial tumors. Cancer Genet Cytogenet 49:95-101.
42. Pejovic T, Himmelmann A, Heim S, Mandahl N, Floderus UM, Furgyik S, Elmfors B, Helm G, Willen H, and Mitelman F (1992b). Prognostic impact of chromosome aberrations in ovarian cancer. Br J Cancer 65:282-286.
43. Persons DL, Hartmann LC, Herath JF, Borell TJ, Cliby WA, Keeney GL, and Jenkins RB (1993). Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas. Am J Pathol 142:733-741.
44. Saiki RK, Scharf S, Faloona F, Mullis KB, Horn GT, Erlich HA, and Arnheim N (1985). Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 230:1350-1354.
45. Saito S, Saito H, Koi S, Sagae S, Kudo R, Saito J, Noda K, and Nakamura Y (1992). Fine-scale deletion mapping of the distal long arm of chromosome 6 in 70 human ovarian cancers. Cancer Res 52:5815-5817.
46. Sasano H and Garrett CT (1992). Oncogenes in gynecological tumors. In: Sasano N, editor. Current topics in pathology, vol 85. Berlin: Springer, 357.
47. Sato T, Saito H, Morita R, Koi S, Lee JH, and Nakamura Y (1991). Allelotype of human ovarian cancer. Cancer Res 51:5118-5122.
48. Sauter G, Deng G, Moch H, Kerschmann R, Matsumura K, De Vries S, George T, Fuentes J, Carroll P, Mihatsch MJ, and Waldman FM (1994). Physical deletion of the p53 gene in bladder cancer: Detection by fluorescence in situ hybridization. Am J Pathol 144:756-766.
49. Tavassoli M, Ruhrberg C, Beaumont V, Reynolds K, Kirkham N, Collins WP, and Farzaneh F (1993). Whole chromosome 17 loss in ovarian cancer. Genes Chromosom Cancer 8:195-198.
50. Thompson FH, Emerson J, Alberts D, Liu Y, Guan XY, Burgess A, Fox S, Taetle R, Weinstein R, Makar R, Powel D, and Trent J (1994a). Clonal chromosome abnormalities in 54 cases of ovarian carcinoma. Cancer Genet Cytogenet 73:33-45.
51. Thompson FH, Liu Y, Emerson J, Weinstein R, Makar R, Trent JM, Taetle R, and Alberts DS (1994b). Simple numeric abnormalities as primary karyotype changes in ovarian carcinoma. Genes Chromosom Cancer 10:262-266.
52. Volz A, Boyle JM, Cann HM, Cottingham RW, Orr HT, and Ziegler A (1994). Report of the Second International Workshop on Human Chromosome 6. Genomics 21:464-472.
53. Wolman SR, Waldman FM, and Balazs M (1993). Complementarity of interphase and metaphase chromosome analysis in human renal tumors. Genes Chromosom Cancer 6:17-23.
54. Yang Feng TL, Li SB, Leung WY, Carcangiu ML, and Schwartz PE (1991). Trisomy 12 and K-ras-2 amplification in human ovarian tumors. Int J Cancer 48:678-681.